Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML

<div>Microscopic features of lung cancer. (a) Adenocarcinoma cells from the first biopsy of a mediastinal lymph node. (b) Small cell transformation from the second biopsy of the hilar lymph node (hematoxylin and eosin stain; original magnifications: (a) ×200; (b) ×400). (c–e) Immunohistochemistry of small cell carcinoma cells with neuroendocrine markers. Synaptophysin (c), CD56 (d), and chromogranin A (e) (c–e, ×400).</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML 

Figure 2 | Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML 